Abstract
The global impact of the coronavirus pandemic cannot be underestimated and highlights the vast societal benefits afforded by vaccinations over the past century. Sadly, during this unprecedented time, we have observed a steep reduction in routine pediatric vaccine administrations nationally.1 Now, more than ever, we must work to ensure timely receipt of all currently available recommended vaccines, especially in vulnerable populations. These efforts must extend beyond primary care settings, beginning with the first vaccine on the childhood immunization schedule: the hepatitis B birth dose. Approximately 1000 US infants are perinatally infected with the hepatitis B virus (HBV) each year.2,3 HBV infection can cause chronic liver disease, with high morbidity and mortality, particularly among those infected as infants. To address this public health concern, the US Department of Health and Human Services set a goal of “zero” perinatal hepatitis B transmission by 2020.4 Hepatitis B vaccination, along with hepatitis B immune globulin when indicated, is the most effective means of preventing perinatal HBV transmission.2,5 In October 2016, the US Advisory Committee on Immunization Practices voted to recommend hepatitis B vaccination of all medically stable infants born weighing ≥2000 g to hepatitis B surface antigen (HBsAg)–negative mothers within the first 24 hours of birth.5 In 2017, the …
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call